Testing effectiveness (Phase 2)Looking for participantsNCT06083922
What this trial is testing
CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Who this might be right for
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center 20